Publications

Export 1318 results:
Sort by: Author Title [ Type  (Desc)] Year
Journal Article
El-Sayed, A., J. Alber, C. Lammler, S. Jager, W. Woter, and H. C. Vázquez, "Comparative study on genotypic properties of Staphylococcus aureus isolated from clinical and subclinical mastitis in Mexico", Veterinaria México, vol. 37, no. 2: UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO, pp. 165, 2006. Abstract
n/a
El-Sayed, A., J. Alber, C. Lämmler, S. Jäger, W. Wolter, and H. C. Vázquez, Comparative study on genotypic properties of Staphylococcus aureus isolated from clinical and subclinical mastitis in Mexico., , vol. 37, issue 2, pp. 165 - 179, 2006. Abstract
n/a
El-Sayed, A., J. Alber, C. Lämmler, S. Jäger, W. Wolter, and H. C. Vázquez, "Comparative study on genotypic properties of Staphylococcus aureus isolated from clinical and subclinical mastitis in Mexico.", Veterinaria Mexico, vol. 37, no. 2, pp. 165–179, 2006. Abstract
n/a
Abu-Seida, A. M., O. El- Tookhy, and A. A. Kawkab, "A Comparison between Surgery and Surgery Adjunctive with Immunotherapy for Treatment of Ocular Squamous Cell Carcinoma in cattle", Egypt. Vet. Med. Assoc, vol. 68, issue 3, 2008. Abstract

n/a

Hemeida, A., P. Sergeant, and H. Vansompel, "Comparison of methods for permanent magnet eddy-current loss computations with and without reaction field considerations in axial flux PMSM", IEEE Transactions on Magnetics, vol. 51, issue 9: IEEE, pp. 1-11, 2015. Abstract
n/a
Hemeida, A., B. Hannon, H. Vansompel, and P. Sergeant, "Comparison of Three Analytical Methods for the Precise Calculation of Cogging Torque and Torque Ripple in Axial Flux PM Machines", Mathematical Problems in Engineering, vol. 2016: Hindawi Publishing Corporation, 2016. Abstract
n/a
Hemeida, A., B. Hannon, H. Vansompel, and P. Sergeant, "Comparison of Three Analytical Methods for the Precise Calculation of Cogging Torque and Torque Ripple in Axial Flux PM Machines", Mathematical Problems in Engineering, vol. 2016: Hindawi Publishing Corporation, 2016. Abstract

n/a

Aly, M. F. A., S. A. Kleijn, K. de Boer, Y. A. A. El-Hady, K. A. Sorour, H. I. Kandil, A. C. Van Rossum, and O. Kamp, "Comparison of three-dimensional echocardiographic software packages for assessment of left ventricular mechanical dyssynchrony and prediction of response to cardiac resynchronization therapy", European Heart Journal-Cardiovascular Imaging: The Oxford University Press, pp. jes218, 2012. Abstract
n/a
Aly, M. F. A., S. A. Kleijn, K. de Boer, Y. A. A. El-Hady, K. A. Sorour, H. I. Kandil, A. C. Van Rossum, and O. Kamp, "Comparison of three-dimensional echocardiographic software packages for assessment of left ventricular mechanical dyssynchrony and prediction of response to cardiac resynchronization therapy", European Heart Journal-Cardiovascular Imaging: The Oxford University Press, pp. jes218, 2012. Abstract
n/a
Aziza, A., A. A. El-Wahab, R. P. Wilson, R. W. Hardy, A. J. G. Tacon, L. M. P. Valente, A. Gouveia, P. Rema, J. Matos, E. F. Gomes, et al., "Complementary responses between hydrolyzed feather meal, fish meal and soybean meal without amino acid supplementation in Nile tilapia Oreochromis niloticus diets.", Journal of Applied Sciences, vol. 19, no. 5: orgz, pp. pp–144, 2017. Abstract
n/a
Fahmy, N. T., J. D. Klena, A. M. R. S. MOHAMED, A. Zayed, and J. T. Villinski, "Complete genome sequence of chikungunya virus isolated from an Aedes aegypti mosquito during an outbreak in Yemen, 2011", Genome Announc., vol. 3, no. 4: Am Soc Microbiol, pp. e00789–15, 2015. Abstract
n/a
Fahmy, N. T., J. D. Klena, A. M. R. S. MOHAMED, A. Zayed, and J. T. Villinski, "Complete genome sequence of chikungunya virus isolated from an Aedes aegypti mosquito during an outbreak in Yemen, 2011", Genome Announc., vol. 3, no. 4: Am Soc Microbiol, pp. e00789–15, 2015. Abstract
n/a
Fahmy, N. T., J. D. Klena, A. M. R. S. MOHAMED, A. Zayed, and J. T. Villinski, "Complete genome sequence of chikungunya virus isolated from an Aedes aegypti mosquito during an outbreak in Yemen, 2011", Genome Announc., vol. 3, no. 4: Am Soc Microbiol, pp. e00789–15, 2015. Abstract
n/a
Fahmy, N. T., J. D. Klena, A. M. R. S. MOHAMED, A. Zayed, and J. T. Villinski, "Complete genome sequence of chikungunya virus isolated from an Aedes aegypti mosquito during an outbreak in Yemen, 2011", Genome Announc., vol. 3, no. 4: Am Soc Microbiol, pp. e00789–15, 2015. Abstract
n/a
Vitrano, A., A. Meloni, W. A. Pollina, M. Karimi, A. El-Beshlawy, M. Hajipour, V. Di Marco, S. H. Ansari, A. Filosa, P. Ricchi, et al., "A complication risk score to evaluate clinical severity of thalassaemia syndromes.", British journal of haematology, vol. 192, issue 3, pp. 626-633, 2021. Abstract

The thalassaemia syndromes (TS) show different phenotype severity. Developing a reliable, practical and global tool to determine disease severity and tailor treatment would be of great value. Overall, 7910 patients were analysed with the aim of constructing a complication risk score (CoRS) to evaluate the probability of developing one or more complications. Nine independent variables were included in the investigation as predictors. Logistic regression models were used for Group A [transfusion-dependent thalassaemia (TDT)], Group B [transfused non-TDT (NTDT)] and Group C (non-transfused NTDT). Statistically significant predictors included age (years), haemoglobin levels, hepatic transaminases [alanine aminotransferase (ALT) and aspartate aminotransferase] and left-ventricular ejection fraction (LVEF) for Group A; age (years), age at first chelation (months), ALT and LVEF for Group B; and age (years), mean serum ferritin (SF) levels and LVEF for Group C. The area under the receiver operating characteristic curve was 84·5%, 82·1% and 80·0% for Groups A, Group B and Group C respectively, suggesting the models had good discrimination. Finally, the CoRS for each group was categorised into four risk classes (low, intermediate, high, and very high) using the centiles of its distribution. In conclusion, we have developed a CoRS for TS that can assist physicians in prospectively tailoring patients' treatment.

Abdelrahman, H. M., F. G. Ceglie, F. G. Erriquens, V. Verrastro, C. M. Rivera, and F. Tittarelli, "Compost Based Growing Media for Organic Melon Seedlings Production", Acta Horticulturae, vol. 933, pp. 99-106, 2012. AbstractWebsite

Two types of compost were produced at the experimental compost facility of
the Mediterranean Agronomic Institute of Bari (IAMB). The green waste compost (GWC) was composed of olive pruning and broccoli residues, and mixed waste compost (MWC) was composed of olive pruning and bovine manure. Both composts have alkaline pH, acceptable salinity content and low C/N ratio. They were evaluated as components of growing media in partial substitution of Sphagnum peat for organic melon seedlings production. A greenhouse trial was carried out to evaluate the composts as a peat substitute for melon seedlings’ growth. Treatments, differentiated on the basis of the volume percentage of both composts, were compared to the control (a mixture of peat, coconut fiber and perlite). Compost-based substrates were analyzed for physical, physicochemical and chemical parameters (bulk density, porosity, pH, EC, nutrients content, etc.). In accordance with the guidelines of organic production, all treatments were fertilized, at the beginning of the trial, with guano. At transplant stage of nursery trial, biometric parameters and nutrient contents of shoots were measured. Compost addition has affected the chemical and physical characteristics of the media. Even though significant differences were observed, recorded values were in the range of acceptability for growing media. In terms of performance, seedling growth in treatments containing 30 and 50% of composts was significantly higher than in control. In terms of peat substitution, good results were obtained even though 10% of peat was used in the tested media.

Sergeant, P., H. Vansompel, A. Hemeida, A. Van den Bossche, and L. Dupre, "A computationally efficient method to determine iron and magnet losses in VSI-PWM fed axial flux permanent magnet synchronous machines", IEEE Transactions on Magnetics, vol. 50, no. 8: IEEE, pp. 1–10, 2014. Abstract
n/a
Sergeant, P., H. Vansompel, A. Hemeida, A. Van den Bossche, and L. Dupre, "A computationally efficient method to determine iron and magnet losses in VSI-PWM fed axial flux permanent magnet synchronous machines", IEEE Transactions on Magnetics, vol. 50, issue 8: IEEE, pp. 1-10, 2014. Abstract
n/a
Gruber-Rouh, T., A. Thalhammer, T. Klingebiel, N. - E. A. Nour-Eldin, T. J. Vogl, K. Eichler, N. Naguib, and M. Beeres, "Computed tomography-guided biopsies in children: accuracy, efficiency and dose usage", Italian Journal of Pediatrics, pp. 43-44, 2017.
Akinyemi, R., F. Sarfo, F. Abd-Allah, Y. Ogun, M. Belo, P. Francis, B. M. Mateus, K. Bateman, P. Naidoo, A. Charway-Felli, et al., "Conceptual framework for establishing the African Stroke Organization.", International journal of stroke : official journal of the International Stroke Society, vol. 16, issue 1, pp. 93-99, 2021. Abstract

Africa is the world's most genetically diverse, second largest, and second most populous continent, with over one billion people distributed across 54 countries. With a 23% lifetime risk of stroke, Africa has some of the highest rates of stroke worldwide and many occur in the prime of life with huge economic losses and grave implications for the individual, family, and the society in terms of mental capital, productivity, and socioeconomic progress. Tackling the escalating burden of stroke in Africa requires prioritized, multipronged, and inter-sectoral strategies tailored to the unique African epidemiological, cultural, socioeconomic, and lifestyle landscape. The African Stroke Organization (ASO) is a new pan-African coalition that brings together stroke researchers, clinicians, and other health-care professionals with participation of national and regional stroke societies and stroke support organizations. With a vision to reduce the rapidly increasing burden of stroke in Africa, the ASO has a four-pronged focus on (1) research, (2) capacity building, (3) development of stroke services, and (4) collaboration with all stakeholders. This will be delivered through advocacy, awareness, and empowerment initiatives to bring about people-focused changes in policy, clinical practice, and public education. In the spirit of the " the ASO will harness the power of diversity, inclusiveness, togetherness, and team work to build a strong, enduring, and impactful platform for tackling stroke in Africa.

El Kassas, M., A. L. Funk, Y. Abd El Latif, A. Vasiliu, A. Sherief, Y. Shimakawa, N. Youssef, A. El Tahan, M. Elbadry, A. M. Farid, et al., "concordance of SVR4 and SVR12 following direct-acting anti-viral treatment in Egypt", Alimentary pharmacology & therapeutics, vol. 47, no. 11, pp. 1564–1566, 2018. Abstract
n/a
Hutchinson, P. J., A. G. Kolias, T. Tajsic, A. Adeleye, A. T. Aklilu, T. Apriawan, A. H. Bajamal, E. J. Barthélemy, I. B. Devi, D. Bhat, et al., "Consensus statement from the International Consensus Meeting on the Role of Decompressive Craniectomy in the Management of Traumatic Brain Injury : Consensus statement.", Acta neurochirurgica, vol. 161, issue 7, pp. 1261-1274, 2019. Abstract

BACKGROUND: Two randomised trials assessing the effectiveness of decompressive craniectomy (DC) following traumatic brain injury (TBI) were published in recent years: DECRA in 2011 and RESCUEicp in 2016. As the results have generated debate amongst clinicians and researchers working in the field of TBI worldwide, it was felt necessary to provide general guidance on the use of DC following TBI and identify areas of ongoing uncertainty via a consensus-based approach.

METHODS: The International Consensus Meeting on the Role of Decompressive Craniectomy in the Management of Traumatic Brain Injury took place in Cambridge, UK, on the 28th and 29th September 2017. The meeting was jointly organised by the World Federation of Neurosurgical Societies (WFNS), AO/Global Neuro and the NIHR Global Health Research Group on Neurotrauma. Discussions and voting were organised around six pre-specified themes: (1) primary DC for mass lesions, (2) secondary DC for intracranial hypertension, (3) peri-operative care, (4) surgical technique, (5) cranial reconstruction and (6) DC in low- and middle-income countries.

RESULTS: The invited participants discussed existing published evidence and proposed consensus statements. Statements required an agreement threshold of more than 70% by blinded voting for approval.

CONCLUSIONS: In this manuscript, we present the final consensus-based recommendations. We have also identified areas of uncertainty, where further research is required, including the role of primary DC, the role of hinge craniotomy and the optimal timing and material for skull reconstruction.

Pennell, D. J., J. B. Porter, M. D. Cappellini, L. L. Chan, A. El-Beshlawy, Y. Aydinok, H. Ibrahim, C. - K. Li, V. Viprakasit, M. S. Elalfy, et al., "Continued Improvement in Myocardial T2* Over Two Years of Deferasirox Therapy in ?-Thalassemia Major Patients with Cardiac Iron Overload", Haematologica, 2011. Abstractcu_pdf.pdf

Background: The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with ?-thalassemia major in the cardiac sub-study of the EPIC trial.

Pennell, D. J., J. B. Porter, M. D. Cappellini, L. L. Chan, A. El-Beshlawy, Y. Aydinok, H. Ibrahim, C. - K. Li, V. Viprakasit, M. S. Elalfy, et al., "Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.", Haematologica, vol. 96, issue 1, pp. 48-54, 2011 Jan. Abstract

BACKGROUND: The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major in the cardiac sub-study of the EPIC trial.

DESIGN AND METHODS: Eligible patients with myocardial T2* greater than 5 to less than 20 ms received deferasirox, with the primary endpoint being the change in T2* from baseline to two years.

RESULTS: Baseline myocardial T2* was severe (> 5 to < 10 ms) in 39 patients, and moderate-to-mild (10 to < 20 ms) in 62 patients. Mean deferasirox dose was 33.1 ± 3.7 mg/kg/d in the one-year core study increasing to 36.1 ± 7.7 mg/kg/d during the second year of treatment. Geometric mean myocardial T2* increased from a baseline of 11.2 to 14.8 ms at two years (P < 0.001). In patients with moderate-to-mild baseline T2*, an increase was seen from 14.7 to 20.1 ms, with normalization (≥ 20 ms) in 56.7% of patients. In those with severe cardiac iron overload at baseline, 42.9% improved to the moderate-to-mild group. The incidence of drug-related adverse events did not increase during the extension relative to the core study and included (≥ 5%) increased serum creatinine, rash and increased alanine aminotransferase.

CONCLUSIONS: Continuous treatment with deferasirox for two years with a target dose of 40 mg/kg/d continued to remove iron from the heart in patients with β-thalassemia major and mild, moderate and severe cardiac siderosis. (Clinicaltrials.gov identifier: NCT 00171821).

Olanow, W. C., K. Kieburtz, P. Odin, A. J. Espay, D. G. Standaert, H. H. Fernandez, A. Vanagunas, A. A. Othman, K. L. Widnell, W. Z. Robieson, et al., "Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.", The Lancet. Neurology, vol. 13, issue 2, pp. 141-9, 2014 Feb. AbstractWebsite

BACKGROUND: Levodopa is the most effective therapy for Parkinson's disease, but chronic treatment is associated with the development of potentially disabling motor complications. Experimental studies suggest that motor complications are due to non-physiological, intermittent administration of the drug, and can be reduced with continuous delivery. We aimed to assess efficacy and safety of levodopa-carbidopa intestinal gel delivered continuously through an intrajejunal percutaneous tube.

METHODS: In our 12-week, randomised, double-blind, double-dummy, double-titration trial, we enrolled adults (aged ≥ 30 years) with advanced Parkinson's disease and motor complications at 26 centres in Germany, New Zealand, and the USA. Eligible participants had jejunal placement of a percutaneous gastrojejunostomy tube, and were then randomly allocated (1:1) to treatment with immediate-release oral levodopa-carbidopa plus placebo intestinal gel infusion or levodopa-carbidopa intestinal gel infusion plus oral placebo. Randomisation was stratified by site, with a mixed block size of 2 or 4. The primary endpoint was change from baseline to final visit in motor off-time. We assessed change in motor on-time without troublesome dyskinesia as a prespecified key secondary outcome. We assessed efficacy in a full-analysis set of participants with data for baseline and at least one post-baseline assessment, and imputed missing data with the last observation carried forward approach. We assessed safety in randomly allocated patients who underwent the percutaneous gastrojejunostomy procedure. This study is registered with ClinicalTrials.gov, numbers NCT00660387 and NCT0357994.

FINDINGS: From baseline to 12 weeks in the full-analysis set, mean off-time decreased by 4.04 h (SE 0.65) for 35 patients allocated to the levodopa-carbidopa intestinal gel group compared with a decrease of 2.14 h (0.66) for 31 patients allocated to immediate-release oral levodopa-carbidopa (difference -1.91 h [95% CI -3.05 to -0.76]; p=0.0015). Mean on-time without troublesome dyskinesia increased by 4.11 h (SE 0.75) in the intestinal gel group and 2.24 h (0.76) in the immediate-release oral group (difference 1.86 [95% CI 0.56 to 3.17]; p=0.0059). In the safety analyses 35 (95%) of 37 patients allocated to the levodopa-carbidopa intestinal gel group had adverse events (five [14%] serious), as did 34 (100%) of 34 patients allocated to the immediate-release oral levodopa-carbidopa group (seven [21%] serious), mainly associated with the percutaneous gastrojejunostomy tube.

INTERPRETATION: Continuous delivery of levodopa-carbidopa with an intestinal gel offers a promising option for control of advanced Parkinson's disease with motor complications. Benefits noted with intestinal gel delivery were of a greater magnitude than were those obtained with medical therapies to date, and our study is, to our knowledge, the first demonstration of the benefit of continuous levodopa delivery in a double-blind controlled study.

FUNDING: AbbVie.